BibTex format
@article{Cardenas:2025:10.1136/bmjopen-2025-107142,
author = {Cardenas, MK and Anza-Ramirez, C and Bernabe-Ortiz, A and Custodio, N and Montesinos, R and Miranda, JJ and Da, Re M and Belon-Hercilla, MV and Lazo-Porras, M and Hawkins, J and Diez-Canseco, F and Moore, G and Whiteley, W and Calvo, RA and Cuba-Fuentes, MS and Landeiro, F and Butler, CR},
doi = {10.1136/bmjopen-2025-107142},
journal = {BMJ Open},
title = {Validation and cost-effectiveness of an mHealth tool for cognitive impairment detection in Peru: protocol for the IMPACT Salud observational study},
url = {http://dx.doi.org/10.1136/bmjopen-2025-107142},
volume = {15},
year = {2025}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - Introduction Dementia is a chronic and progressive neurological condition characterised by cognitive and functional impairment. It is often associated with multimorbidity and imposes a significant economic burden on healthcare systems and families, especially in low-income and middle-income countries. In Peru, where dementia cases are increasing rapidly, timely detection and referral for diagnosis is crucial. This protocol is part of the IMPACT Salud project in Peru. Here, we focus on a specific component aimed at validating an mHealth tool for the detection of cognitive and functional impairment and assessing its cost-effectiveness. We will also assess changes in cognitive and functional impairment as well as health economic outcomes over 1 year.Methods and analysis This observational study will be conducted in four geographically diverse regions of Peru. Community health workers are expected to contact approximately 32 000 participants (≥60 years) to apply an mHealth-enabled tool that includes cognitive and functional instruments: Ascertain Dementia 8, Peruvian version of Rowland Universal Dementia Assessment Scale and Pfeffer Functional Activities Questionnaire. From this large sample, we aim to find 3600 participants and their study partners to enrol and interview at baseline regarding sociodemographic characteristics, lifestyles, comorbidities and health economic data including resource use, costs and health-related quality of life (HR-QoL). Psychologists, blind to previous results, will assess dementia stage of the participants using an abbreviated Clinical Dementia Rating (CDR) scale. At 6-month follow-up, participants will complete a brief health economics questionnaire on resource use, costs and HR-QoL. To validate the accuracy of the detection tool, a subsample of 600 participants who completed the baseline will undergo a gold-standard clinical neuropsychological assessment. This subsample will participate in a 12-month follow-up, including healt
AU - Cardenas,MK
AU - Anza-Ramirez,C
AU - Bernabe-Ortiz,A
AU - Custodio,N
AU - Montesinos,R
AU - Miranda,JJ
AU - Da,Re M
AU - Belon-Hercilla,MV
AU - Lazo-Porras,M
AU - Hawkins,J
AU - Diez-Canseco,F
AU - Moore,G
AU - Whiteley,W
AU - Calvo,RA
AU - Cuba-Fuentes,MS
AU - Landeiro,F
AU - Butler,CR
DO - 10.1136/bmjopen-2025-107142
PY - 2025///
SN - 2044-6055
TI - Validation and cost-effectiveness of an mHealth tool for cognitive impairment detection in Peru: protocol for the IMPACT Salud observational study
T2 - BMJ Open
UR - http://dx.doi.org/10.1136/bmjopen-2025-107142
UR - https://doi.org/10.1136/bmjopen-2025-107142
VL - 15
ER -